What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2. "WOEST 2"

Active, not recruiting

Phase Results N/A

Summary of Purpose

The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with stenting, is still unknown. For these patients current North American and European guidelines recommend a triple therapy strategy, including vitamin K antagonists (VKA), aspirin and...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 April 2018.

1 Jun 2014 10 Dec 2015 1 Jun 2019 1 Dec 2019 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Probability Sample

Contacts